CLS - Celestica Inc.

NYSE - NYSE Delayed Price. Currency in USD
7.87
+0.09 (+1.16%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close7.78
Open7.80
Bid7.87 x 900
Ask7.88 x 1000
Day's Range7.80 - 7.95
52 Week Range5.95 - 10.50
Volume207,780
Avg. Volume343,771
Market Cap1.013B
Beta (3Y Monthly)0.77
PE Ratio (TTM)7.69
EPS (TTM)1.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.03
  • Here is What Hedge Funds Think About Celestica Inc. (CLS)
    Insider Monkey

    Here is What Hedge Funds Think About Celestica Inc. (CLS)

    Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

  • Moody's

    Celestica Inc. -- Moody's announces completion of a periodic review of ratings of Celestica Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Celestica Inc. Toronto, October 28, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Celestica Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • 5 Undervalued Stocks to Buy
    InvestorPlace

    5 Undervalued Stocks to Buy

    [Editor's note: "5 Undervalued Stocks to Buy" was previously published in September 2019. It has since been updated to include the most relevant information available.]Overall, the stock market continued its improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later.Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally. * 7 Top-Notch REITs to Buy for Income Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower.With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently and has been trading in the $58-$59 range ever since.The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million), but the Q3 report doesn't look as bright.Now that Sony is trading at yearly highs, investors need not sell the stock just yet.When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported respectable Q3/2019 results recently, but it didn't move the CLS stock out of its $6 trading range.The company supplies equipment in ATS aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Stocks to Buy With 100% Upside Potential Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. AbbVie (ABBV)Source: Shutterstock Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough.In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few year's time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Source: Shutterstock Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fall began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Safe Stocks to Buy and Hold Through 2020 Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Source: Apple Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to its pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y (its next report was expected toward the end of October). The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20.In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 4.95%. If Vodafone grows its UK business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cybersecurity Stocks to Keep Your Portfolio Safe * 7 Top-Notch REITs to Buy for Income * 5 Reasons Why I Still Believe in Hexo Stock The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

  • Celestica (CLS) Beats Q3 Earnings and Revenue Estimates
    Zacks

    Celestica (CLS) Beats Q3 Earnings and Revenue Estimates

    Celestica (CLS) delivered earnings and revenue surprises of 8.33% and 5.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Celestica Announces Third Quarter 2019 Financial Results

    TORONTO, Oct. 24, 2019 -- Celestica Inc. (TSX: CLS)(NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today.

  • Does Celestica Inc.'s (TSE:CLS) CEO Salary Reflect Performance?
    Simply Wall St.

    Does Celestica Inc.'s (TSE:CLS) CEO Salary Reflect Performance?

    Rob Mionis became the CEO of Celestica Inc. (TSE:CLS) in 2015. First, this article will compare CEO compensation with...

  • Analysts Estimate Celestica (CLS) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Celestica (CLS) to Report a Decline in Earnings: What to Look Out for

    Celestica (CLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Celestica Releases 2018 Sustainability Report

    TORONTO, Sept. 30, 2019 -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today.

  • Did You Manage To Avoid Celestica's (TSE:CLS) 32% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Celestica's (TSE:CLS) 32% Share Price Drop?

    Celestica Inc. (TSE:CLS) shareholders should be happy to see the share price up 13% in the last month. But that cannot...

  • Celestica (CLS) Moves to Strong Buy: Rationale Behind the Upgrade
    Zacks

    Celestica (CLS) Moves to Strong Buy: Rationale Behind the Upgrade

    Celestica (CLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • Jabil (JBL) Catches Eye: Stock Jumps 7.8%
    Zacks

    Jabil (JBL) Catches Eye: Stock Jumps 7.8%

    Jabil (JBL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Itron (ITRI) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Itron (ITRI) Soars to 52-Week High, Time to Cash Out?

    Itron (ITRI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Celestica Inc. (CLS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Celestica Inc. (CLS) Q2 2019 Earnings Call Transcript

    CLS earnings call for the period ending June 30, 2019.

  • Celestica (CLS) Q2 Earnings Meet Estimates
    Zacks

    Celestica (CLS) Q2 Earnings Meet Estimates

    Celestica (CLS) delivered earnings and revenue surprises of 0.00% and -0.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Celestica Announces Second Quarter 2019 Financial Results

    TORONTO, July 24, 2019 -- Celestica Inc. (TSX: CLS)(NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today.

  • Factors Setting the Tone for Celestica (CLS) in Q2 Earnings
    Zacks

    Factors Setting the Tone for Celestica (CLS) in Q2 Earnings

    Celestica's (CLS) Q2 earnings are likely to benefit from synergies from Impakt and Atrenne buyouts; and solid adoption of JDM solutions. However, soft demand from OEM customers remains headwind.

  • Is Celestica (CLS) a Great Value Stock Right Now?
    Zacks

    Is Celestica (CLS) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Plexus (PLXS) Q3 Earnings Miss Estimates, Revenues Up Y/Y
    Zacks

    Plexus (PLXS) Q3 Earnings Miss Estimates, Revenues Up Y/Y

    Plexus' (PLXS) third-quarter results benefit from robust revenues from Healthcare/Life Sciences and Aerospace/Defense sectors despite unfavorable mix, which hurt margins.

  • Earnings Preview: Celestica (CLS) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Celestica (CLS) Q2 Earnings Expected to Decline

    Celestica (CLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    S&P Reaches New Record After Trade Ceasefire

    S&P; Reaches New Record After Trade Ceasefire

  • Should Value Investors Buy Celestica (CLS) Stock?
    Zacks

    Should Value Investors Buy Celestica (CLS) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • GlobeNewswire

    AbelConn Electronics Receives 4-Star Supplier Excellence Award from Raytheon

    AbelConn Electronics, a Celestica company, announced today that it has been awarded a Raytheon Integrated Defense Systems 4-Star Supplier Excellence Award. Raytheon’s Integrated Defense Systems business instituted the annual Supplier Excellence Awards program to recognize suppliers who have provided outstanding service and partnership in exceeding customer requirements. “Meeting our customers’ delivery and quality requirements is core to our business and I’m proud of our team for consistently exceeding Raytheon’s high standards,” said Chris Milano, President of AbelConn.

  • GlobeNewswire

    Celestica named One of Canada’s Best 50 Corporate Citizens by Corporate Knights

    TORONTO, June 04, 2019 -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world's most innovative companies, today.

  • Do Options Traders Know Something About Celestica (CLS) Stock We Don't?
    Zacks

    Do Options Traders Know Something About Celestica (CLS) Stock We Don't?

    Investors need to pay close attention to Celestica (CLS) stock based on the movements in the options market lately.